Patents by Inventor Liat Rockah
Liat Rockah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240131121Abstract: The present invention provides a non-naturally occurring composition comprising a CRISPR nuclease comprising a sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3 or a nucleic acid molecule comprising a sequence encoding the CRISPR nuclease.Type: ApplicationFiled: April 5, 2023Publication date: April 25, 2024Applicant: EmendoBio Inc.Inventors: David Baram, Lior Izhar, Asael Herman, Liat Rockah, Nadav Marbach-Bar, Nurit Meron, Joseph Georgeson
-
Patent number: 11946077Abstract: The present invention provides a non-naturally occurring composition comprising a CRISPR nuclease comprising a sequence having at least 95% identity to the amino acid sequence selected from the group consisting of SEQ ID NOs: 1-8 or a nucleic acid molecule comprising a sequence encoding the CRISPR nuclease.Type: GrantFiled: June 4, 2021Date of Patent: April 2, 2024Inventors: Lior Izhar, Liat Rockah, Nadav Marbach Bar, Nurit Meron
-
Publication number: 20240002840Abstract: A composition comprising a non-naturally occurring RNA molecule, the RNA molecule comprising an RNA scaffold portion, the RNA scaffold portion having the structure: crRNA repeat sequence portion-Linker portion-tracrRNA portion; wherein the RNA scaffold portion forms a complex with and targets an OMNI-50 CRISPR nuclease to a DNA target site having complementarity to a guide sequence portion of the RNA molecule.Type: ApplicationFiled: November 3, 2021Publication date: January 4, 2024Applicants: EmendoBio Inc.Inventors: Lior Izhar, Liat Rockah, Nadav Marbach Bar
-
Publication number: 20230383273Abstract: The present invention provides a non-naturally occurring composition comprising a CRISPR nuclease comprising a sequence having at least 90% identity to the amino acid sequence selected from the group consisting of SEQ ID NOs: 1-8 or a nucleic acid molecule comprising a sequence encoding the CRISPR nuclease.Type: ApplicationFiled: October 20, 2021Publication date: November 30, 2023Applicant: EmendoBio Inc.Inventors: Lior Izhar, Liat Rockah, Nadav Marbach Bar, Nurit Meron
-
Publication number: 20230303989Abstract: The present invention provides a non-naturally occurring composition comprising a CRISPR nuclease comprising a sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1 or a nucleic acid molecule comprising a sequence encoding the CRISPR nuclease.Type: ApplicationFiled: February 7, 2022Publication date: September 28, 2023Applicant: EmendoBio Inc.Inventors: Lior Izhar, Nadav Marbach Bar, Liat Rockah, Nurit Meron, Ophir Adiv Tal, Ariel Gispan, Idit Buch, Nir Hecht
-
Patent number: 11666641Abstract: The present invention provides a non-naturally occurring composition comprising a CRISPR nuclease comprising a sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3 or a nucleic acid molecule comprising a sequence encoding the CRISPR nuclease.Type: GrantFiled: April 30, 2020Date of Patent: June 6, 2023Assignee: EMENDOBIO INC.Inventors: David Baram, Lior Izhar, Asael Herman, Liat Rockah, Nadav Marbach-Bar, Nurit Meron, Joseph Georgeson
-
Publication number: 20230122086Abstract: The present invention provides a non-naturally occurring composition comprising a CRISPR nuclease comprising a sequence having at least 95% identity to the amino acid sequence selected from the group consisting of SEQ ID NOs: 1-8 or a nucleic acid molecule comprising a sequence encoding the CRISPR nuclease.Type: ApplicationFiled: June 4, 2021Publication date: April 20, 2023Applicant: EmendoBio Inc.Inventors: Lior Izhar, Liat Rockah, Nadav Marbach Bar, Nurit Meron
-
Publication number: 20220387515Abstract: Methods for inactivating in a cell a mutant allele of the elastase, neutrophil expressed gene (ELANE gene) gene having a mutation associated with severe congenital neutropenia (SCN) or cyclic neutropenia (CyN) and which cell is heterozygous at one or more polymorphic sites selected from the group consisting of: rs10424470, rs4807932, rs10414837, rs376107533, rs3761010, rs351108, rs3826946, rs10413889, rs3761007, rs10409474, rs3761005, rs351107, rs3761001, rs740021, rs781452480, rs371057361, rs570466264, rs1041904080, rs7250194, rs17216649, rs199720952, rs6510983, rs17223066, rs7255385, rs9749274, rs111361200, rs112639467, rs141213775, rs28591229, rs10469327, rs3834645, rs1683564, rs71335276, and rs8107095, the method comprising introducing to the cell a composition comprising: a CRISPR nuclease or a sequence encoding the CRISPR nuclease; and a first RNA molecule comprising a guide sequence portion having 21-30 nucleotides, wherein a complex of the CRISPR nuclease and the first RNA molecule affects a douType: ApplicationFiled: November 5, 2020Publication date: December 8, 2022Applicant: EmendoBio Inc.Inventors: David Baram, Lior Izhar, Asael Herman, Rafi Emmanuel, Liat Rockah, Nadav Marbach Bar, Michal Golan Mashiach, Joseph Georgeson
-
Publication number: 20220213456Abstract: The present invention provides a non-naturally occurring composition comprising a CRISPR nuclease comprising a sequence having at least 95% identity to the amino acid sequence selected from the group consisting of SEQ ID NOs: 1-4 or 149-166 or a nucleic acid molecule comprising a sequence encoding the CRISPR nuclease.Type: ApplicationFiled: April 30, 2020Publication date: July 7, 2022Applicant: EmendoBio Inc.Inventors: David Baram, Lior Izhar, Asael Herman, Liat Rockah, Nadav Marbach-Bar, Nurit Meron, Joseph Georgeson
-
Publication number: 20220202913Abstract: The present invention provides a non-naturally occurring composition comprising a CRISPR nuclease comprising a sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3 or a nucleic acid molecule comprising a sequence encoding the CRISPR nuclease.Type: ApplicationFiled: April 30, 2020Publication date: June 30, 2022Applicant: EmendoBio Inc.Inventors: David Baram, Lior Izhar, Asael Herman, Liat Rockah, Nadav Marbach-Bar, Nurit Meron, Joseph Georgeson
-
Publication number: 20220154157Abstract: The present invention is directed to, inter glia, composition and methods for genome editing. Specifically, a non-naturally occurring SpCas9 variant having an amino acid substitution at position K929, H930, or at both position K929 and H930.Type: ApplicationFiled: February 4, 2020Publication date: May 19, 2022Applicant: EmendoBio Inc.Inventors: David Baram, Lior Izhar, Asael Herman, Liat Rockah, Nadav Marbach Bar, Rafi Emmanuel
-
Publication number: 20210130804Abstract: Methods for inactivating in a cell a mutant allele of the elastase, neutrophil expressed gene (ELANE gene) gene having a mutation associated with severe congenital neutropenia (SCN) or cyclic neutropenia (CyN) wherein the mutant allele is selected from the group consisting of the ELANE mutants set forth in Table 1, the method comprising introducing to the cell a composition comprising: a CRISPR nuclease or a sequence encoding the CRISPR nuclease; and a first RNA molecule comprising a guide sequence portion having 17-30 nucleotides, wherein a complex of the CRISPR nuclease and the first RNA molecule affects a double strand break in the mutant allele of the ELANE gene the method optionally further comprising introduction of a second RNA molecule comprising a guide sequence portion capable of complexing with a CRISPR nuclease, wherein the complex of the second RNA molecule and CRISPR nuclease affects a second double strand break in the ELANE gene.Type: ApplicationFiled: November 5, 2020Publication date: May 6, 2021Applicant: EmendoBio Inc.Inventors: David Baram, Lior Izhar, Asael Herman, Rafi Emmanuel, Liat Rockah, Nadav Marbach-Bar, Michal Golan Mashiach, Joseph Georgeson